EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Date of report 13.05.2025
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
keywords
- riik ja ühiskond
- seltsid
- ühingud
- eriarstiabi
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Scores and ratings
Reputation score
Credit Score
Open the reports you want to print
Employees and salaries
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Number of employees and estimated average salaries2024 II | 2024 III | 2024 IV | 2025 I | |
Number of employees | ...... | ...... | ...... | ...... |
Average gross salary | ...... | ...... | ...... | ...... |
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Employee taxes and performance analysisQuarter | Labor taxes paid | Number of employees | Turnover Per Employee | Profit per employee |
---|---|---|---|---|
2025 I | ...... | ...... | ...... | ...... |
2024 IV | ...... | ...... | ...... | ...... |
2024 III | ...... | ...... | ...... | ...... |
2024 II | ...... | ...... | ...... | ...... |
2024 I | ...... | ...... | ...... | ...... |
2023 IV | ...... | ...... | ...... | ...... |
2023 III | ...... | ...... | ...... | ...... |
2023 II | ...... | ...... | ...... | ...... |
2023 I | ...... | ...... | ...... | ...... |
2022 IV | ...... | ...... | ...... | ...... |
2022 III | ...... | ...... | ...... | ...... |
2022 II | ...... | ...... | ...... | ...... |
2022 I | ...... | ...... | ...... | ...... |
2021 IV | ...... | ...... | ...... | ...... |
2021 III | ...... | ...... | ...... | ...... |
2021 II | ...... | ...... | ...... | ...... |
2021 I | ...... | ...... | ...... | ...... |
2020 IV | ...... | ...... | ...... | ...... |
2020 III | ...... | ...... | ...... | ...... |
2020 II | ...... | ...... | ...... | ...... |
2020 I | ...... | ...... | ...... | ...... |
2019 IV | ...... | ...... | ...... | ...... |
2019 III | ...... | ...... | ...... | ...... |
2019 II | ...... | ...... | ...... | ...... |
2019 I | ...... | ...... | ...... | ...... |
2018 IV | ...... | ...... | ...... | ...... |
2018 III | ...... | ...... | ...... | ...... |
2018 II | ...... | ...... | ...... | ...... |
2018 I | ...... | ...... | ...... | ...... |
2017 IV | ...... | ...... | ...... | ...... |
2017 III | ...... | ...... | ...... | ...... |
2017 II | ...... | ...... | ...... | ...... |
2017 I | ...... | ...... | ...... | ...... |
2016 IV | ...... | ...... | ...... | ...... |
2016 III | ...... | ...... | ...... | ...... |
2016 II | ...... | ...... | ...... | ...... |
2016 I | ...... | ...... | ...... | ...... |
2015 IV | ...... | ...... | ...... | ...... |
2015 III | ...... | ...... | ...... | ...... |
2015 II | ...... | ...... | ...... | ...... |
2015 I | ...... | ...... | ...... | ...... |
Deciders and beneficiaries
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Decision-makersFormer decision-makers
......
Credit Score: Trustworthy
Reputation score: 930
Date of birth: ......
Active relations 1
0 followers
......
Credit Score: Trustworthy
Reputation score: 930
Date of birth: ......
Active relations 1
3 followers
......
Credit Score: Trustworthy
Reputation score: 930
Date of birth: ......
Active relations 1
0 followers
......
Credit Score: Trustworthy
Reputation score: 930
Date of birth: ......
Active relations 1
0 followers
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Former decision-makers......
Credit Score: Trustworthy
Reputation score: 1490
Date of birth: ......
Active relations 2
14 followers
......
Credit Score: None
Reputation score: None
Date of birth: ......
Active relations 0
0 followers
......
Credit Score: None
Reputation score: None
Date of birth: ......
Active relations 0
0 followers
......
Credit Score: None
Reputation score: None
Date of birth: ......
Active relations 0
0 followers
......
Credit Score: Trustworthy
Reputation score: 930
Date of birth: ......
Active relations 1
3 followers
......
Credit Score: Trustworthy
Reputation score: 100
Date of birth: ......
Active relations 1
1 follower
......
Credit Score: None
Reputation score: None
Date of birth: ......
Active relations 0
0 followers
......
Credit Score: Trustworthy
Reputation score: 630
Date of birth: ......
Active relations 1
2 followers
......
Credit Score: Neutral
Reputation score: 110
Date of birth: ......
Active relations 1
3 followers
......
Credit Score: Trustworthy
Reputation score: 510
Date of birth: ......
Active relations 1
1 follower
......
Credit Score: Trustworthy
Reputation score: 460
Date of birth: ......
Active relations 1
4 followers
......
Credit Score: None
Reputation score: None
Date of birth: ......
Active relations 0
0 followers
......
Credit Score: Trustworthy
Reputation score: 360
Date of birth: ......
Active relations 1
1 follower
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
History of right of representationFinances and assets
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE ...
GoodwillEUR | 2023 | 2024 | 2025 | Trend |
Goodwill | ...... | ...... | ...... | |
Goodwill | ...... | ...... | ...... |
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Taxes paid and estimated average salaries2021 | 2022 | 2023 | 2024 | |
National taxes | ...... | ...... | ...... | ...... |
Labor taxes | ...... | ...... | ...... | ...... |
Average gross salary | ...... | ...... | ...... | ...... |
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Quarterly indicatorsQuarter | Turnover | Taxed turnover | Labour productivity | Labour productivity | Employees | National taxes | Labor taxes |
---|---|---|---|---|---|---|---|
2024 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2024 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2024 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2023 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2022 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2022 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2022 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2022 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2021 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2021 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2021 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2021 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2020 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2020 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2020 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2020 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2019 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2019 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2019 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2019 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2018 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2018 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2018 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2018 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2017 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2017 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2017 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2017 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2016 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2016 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2016 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2016 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2015 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2015 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2015 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2015 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Sales revenue by business arearevenue
Field of activity | EMTAK code | Sales revenue (2023) | Sales revenue % |
Provision of specialist care | 86221 | - | 0,00 |
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE ...
Sales revenue by countryTurnover EUR | 2023 | 2024 prognosis | 2025 prognosis | Trend |
Total sales | ...... | ...... | ...... | |
Estonia | ...... | ...... | ...... | |
Total exports | ...... | ...... | ...... |
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE ...
Financial indicators and prognosisFinancial indicators | 2023 | 2024 Prognosis | 2025 Prognosis |
Trend |
TURNOVER | ...... | ...... | ...... | |
Estonia | ...... | ...... | ...... | |
Other countries | ...... | ...... | ...... | |
INTEREST INCOME | ...... | ...... | ...... | |
OTHER BUSINESS INCOME | ...... | ...... | ...... | |
TURNOVER IN RELATED COMPANY | ...... | ...... | ...... | |
AVERAGE MONTHLY TURNOVER | ...... | ...... | ...... | |
Available credit (credit limit) | ...... | ...... | ...... | |
Settlement dates | ...... | ...... | ...... | |
RECEIVED GRANTS € | ...... | ...... | ...... | |
TENDERS WON € | ...... | ...... | ...... | |
ASSETS | ...... | ...... | ...... | |
Current assets | ...... | ...... | ...... | |
Fixed assets | ...... | ...... | ...... | |
LIABILITIES | ...... | ...... | ...... | |
Short-term liabilities | ...... | ...... | ...... | |
Long-term liabilities | ...... | ...... | ...... | |
EQUITY | ...... | ...... | ...... | |
Share-(equity capital) | ...... | ...... | ...... | |
Retained profits | ...... | ...... | ...... | |
Net profit | ...... | ...... | ...... | |
NET WORKING CAPITAL | ...... | ...... | ...... | |
NUMBER OF EMPLOYEES | ...... | ...... | ...... |
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE ...
Financial raiting: "GOOD" (2025 prognosis)Multipliers and income levels | 2024 prognosis | 2025 prognosis |
Trend |
LIQUIDITY | ...... | ...... | |
Net Working capital | ...... | ...... | |
Short-term debt coverage ratio (X) | ...... | ...... | |
EFFECTIVENESS | ...... | ...... | |
Debt to assets ratio (X) | ...... | ...... | |
Capitalisation multiplier (X) | ...... | ...... | |
USE OF LOAN CAPITAL | ...... | ...... | |
Turnover ratio of fixed assets (X) | ...... | ...... | |
PROFITABILITY | ...... | ...... | |
Sales revenues (%) | ...... | ...... | |
Total asset revenues (%) | ...... | ...... | |
Equity revenues (%) | ...... | ...... |
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Annual reportsYear | Period | Submitted | Report PDF |
---|---|---|---|
2023 | 01.01.2023–31.12.2023 | 17.06.2024 | ...... |
2022 | 01.01.2022–31.12.2022 | 29.06.2023 | ...... |
2021 | 01.01.2021–31.12.2021 | 30.06.2022 | ...... |
2020 | 01.01.2020–31.12.2020 | 21.06.2021 | ...... |
2019 | 01.01.2019–31.12.2019 | 26.10.2020 | ...... |
2018 | 01.01.2018–31.12.2018 | 25.06.2019 | ...... |
2017 | 01.01.2017–31.12.2017 | 21.06.2018 | ...... |
2016 | 01.01.2016–31.12.2016 | 30.06.2017 | ...... |
2015 | 01.01.2015–31.12.2015 | 21.06.2016 | ...... |
2014 | 01.01.2014–31.12.2014 | 25.06.2015 | ...... |
2013 | 01.01.2013–31.12.2013 | 27.06.2014 | ...... |
2012 | 01.01.2012–31.12.2012 | 29.06.2013 | ...... |
2011 | 01.01.2011–31.12.2011 | 01.07.2012 | ...... |
2010 | 01.01.2010–31.12.2010 | 30.06.2011 | ...... |
2009 | 01.01.2009–31.12.2009 | 29.06.2010 | ...... |
Liabilities and debts
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Credit score history and prognosis... €
......
Business risk classes:
Trustworthy NeutralEESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Reports and assets-liabilities overview 13.05.2025EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Claims historyTotal debt claims: ...... €
...... | ...... |
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Income (turnover) and expenditure (taxes paid)Quarter | Turnover | Taxed turnover | National taxes paid | Labor taxes paid | Number of employees |
---|---|---|---|---|---|
2024 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2024 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2024 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2023 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2022 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2022 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2022 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2022 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2021 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2021 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2021 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2021 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2020 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2020 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2020 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2020 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2019 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2019 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2019 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2019 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2018 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2018 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2018 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2018 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2017 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2017 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2017 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2017 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2016 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2016 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2016 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2016 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2015 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2015 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2015 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2015 I | * ...... € | ...... € | ...... € | ...... € | ...... |
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Bailiff's enforcement proceedings as of 13.05.2025Bailiff's enforcement proceedings MISSING
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Regulations of the Payment Order Department as of 13.05.2025Regulations of the Payment Order Department MISSING
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Court orders in the register as of 13.05.2025Court order MISSING
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Decisions of the Consumer Disputes Committee as of 13.05.2025Consumer disputes MISSING
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Court hearings as of 13.05.2025Court hearings MISSING
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Rulings as of 13.05.2025Court settlemets MISSING
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Notices and announcements as of 13.05.2025Announcements MISSING
Marketing
Business network
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Business networkSign in
To expand your connections, log in to the "Networks" environment
Beneficiaries network
EESTI IMMUNOLOOGIDE JA ALLERGOLOOGIDE SELTS MTÜ
Networks - BeneficiariesSign in
To expand your connections, log in to the "Networks" environment
Monitoring events
Filter
Dropdown
Dropdown
Neutral
Positive
Negative
11.04.2025
Change in credit recommendation
Previous credit recommendation: yes
New credit recommendation: no
11.04.2025
Change in credit limit
Credit limit decreased (0 EUR)
14.01.2025
Change in credit limit
Credit limit increased (300 EUR)
13.01.2025
The declaration of turnover
Declared taxable sales amounted to 0 € of labor taxes were paid for the fourth quarter of 2024, which is 0% (0 €) higher, than the preceding quarter.
13.01.2025
Employment data update
0 employee(s) joined the organization fourth quarter of 2024, and the average salary was 0 € per month, which is 0% (0 €) higher than the preceding quarter.
(The average salary for the last 4 quarters was 0 €)
No monitoring events found.
Failed to load monitoring events.